The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells

Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development

(2012) Valentina Caracciolo et al.   CELL CYCLE

A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261

(2012) Keith C. Bible et al.   GYNECOLOGIC ONCOLOGY

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

(2011) B. Holkova et al.   CLINICAL CANCER RESEARCH

Targeting Polo-like Kinase in Cancer Therapy

(2010) Y. Degenhardt et al.   CLINICAL CANCER RESEARCH

Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1

(2008) Anna V. Hoekstra et al.   GYNECOLOGIC ONCOLOGY

AKT Is Activated in an Ataxia-Telangiectasia and Rad3-Related-Dependent Manner in Response to Temozolomide and Confers Protection against Drug-Induced Cell Growth Inhibition

(2008) S. Caporali et al.   MOLECULAR PHARMACOLOGY

Flavopiridol Suppresses Tumor Necrosis Factor-Induced Activation of Activator Protein-1, c-Jun N-Terminal Kinase, p38 Mitogen-Activated Protein Kinase (MAPK), p44/p42 MAPK, and Akt, Inhibits Expression of Antiapoptotic Gene Products, and Enhances Apoptosis through Cytochrome c Release and Caspase Activation in Human Myeloid Cells

(2008) Y. Takada et al.   MOLECULAR PHARMACOLOGY